Shen K, He S, He Y
Department of General Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Chin Med J (Engl). 1998 Dec;111(12):1075-8.
To explore the effects of proglumide, a gastrin receptor antagonist, on the amount of viable cells, synthesis of DNA and protein, and cell proliferation cycle in human large intestine carcinoma SW480 cell line in order to provide experimental basis for treatment of large intestine carcinoma using proglumide.
Large intestine carcinoma SW480 cells at logarithmic growth stage were cultivated with different concentrations of proglumide for different periods of time, then the amount of viable cells was determined by MTT colorimetric analysis. The SW480 cells were cultivated with proglumide, pentagastrin, proglumide + pentagastrin for the same period of time, then the contents of DNA and protein and the cell proliferation cycle were determined by flow-cytometry.
The amount of viable cells, synthesis of DNA and protein, distribution of cell cycle, and proliferation index (PI) in the proglumide group did not differ significantly from those in the pentagastrin group (P > 0.05). The amount of viable cells in the pentagastrin group was significantly higher than that in the pentagastrin group (P < 0.01). In the proglumide + pentagastrin group the amount of viable cells, synthesis of DNA and protein, amount of S and G2M phase cells, and PI were all significantly lower than those in the pentagastrin group (all P < 0.01), and the amount of G0/G1 phase cells was significantly higher than that in the pentagastrin group (P < 0.01), but none of the above differed from those in the control group (all P > 0.05).
Proglumide has no obvious effect on the growth of human large intestine carcinoma SW480 cell line, but can inhibit the growth-promoting effect of pentagastrin on large intestine carcinoma cells. The mechanism may be that proglumide inhibits the promoting effect of pentagastrin on the synthesis of DNA and protein of carcinoma cells, and then inhibits carcinoma cell growth from G0/G1 phase to S and G2M phase.
探讨胃泌素受体拮抗剂丙谷胺对人大肠癌SW480细胞系活细胞数量、DNA和蛋白质合成及细胞增殖周期的影响，为丙谷胺治疗大肠癌提供实验依据。
将对数生长期的人大肠癌SW480细胞用不同浓度丙谷胺培养不同时间，采用MTT比色分析法测定活细胞数量。将SW480细胞分别用丙谷胺、五肽胃泌素、丙谷胺 + 五肽胃泌素培养相同时间，采用流式细胞术检测DNA和蛋白质含量及细胞增殖周期。
丙谷胺组活细胞数量、DNA和蛋白质合成、细胞周期分布及增殖指数（PI）与五肽胃泌素组相比差异无统计学意义（P > 0.05）。五肽胃泌素组活细胞数量明显高于对照组（P < 0.01）。丙谷胺 + 五肽胃泌素组活细胞数量、DNA和蛋白质合成、S期和G2M期细胞数量及PI均明显低于五肽胃泌素组（均P < 0.01），G0/G1期细胞数量明显高于五肽胃泌素组（P < 0.01），但上述各项与对照组相比差异均无统计学意义（均P > 0.05）。
丙谷胺对人大肠癌SW480细胞系生长无明显影响，但可抑制五肽胃泌素对大肠癌细胞的促生长作用。其机制可能是丙谷胺抑制五肽胃泌素对癌细胞DNA和蛋白质合成的促进作用，进而抑制癌细胞从G0/G1期向S期和G2M期的生长。
